JP2014515758A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515758A5
JP2014515758A5 JP2014508507A JP2014508507A JP2014515758A5 JP 2014515758 A5 JP2014515758 A5 JP 2014515758A5 JP 2014508507 A JP2014508507 A JP 2014508507A JP 2014508507 A JP2014508507 A JP 2014508507A JP 2014515758 A5 JP2014515758 A5 JP 2014515758A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
pharmaceutically acceptable
alkylene
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014508507A
Other languages
English (en)
Japanese (ja)
Other versions
JP5902293B2 (ja
JP2014515758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/034959 external-priority patent/WO2012148994A1/en
Publication of JP2014515758A publication Critical patent/JP2014515758A/ja
Publication of JP2014515758A5 publication Critical patent/JP2014515758A5/ja
Application granted granted Critical
Publication of JP5902293B2 publication Critical patent/JP5902293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014508507A 2011-04-25 2012-04-25 ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 Active JP5902293B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161478642P 2011-04-25 2011-04-25
US61/478,642 2011-04-25
US201161537908P 2011-09-22 2011-09-22
US61/537,908 2011-09-22
US201161576471P 2011-12-16 2011-12-16
US61/576,471 2011-12-16
PCT/US2012/034959 WO2012148994A1 (en) 2011-04-25 2012-04-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016044089A Division JP2016193884A (ja) 2011-04-25 2016-03-08 ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法

Publications (3)

Publication Number Publication Date
JP2014515758A JP2014515758A (ja) 2014-07-03
JP2014515758A5 true JP2014515758A5 (cg-RX-API-DMAC7.html) 2015-06-18
JP5902293B2 JP5902293B2 (ja) 2016-04-13

Family

ID=47072720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014508507A Active JP5902293B2 (ja) 2011-04-25 2012-04-25 ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
JP2016044089A Pending JP2016193884A (ja) 2011-04-25 2016-03-08 ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016044089A Pending JP2016193884A (ja) 2011-04-25 2016-03-08 ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法

Country Status (11)

Country Link
US (5) US9079909B2 (cg-RX-API-DMAC7.html)
EP (1) EP2701510B1 (cg-RX-API-DMAC7.html)
JP (2) JP5902293B2 (cg-RX-API-DMAC7.html)
AU (1) AU2012249801B2 (cg-RX-API-DMAC7.html)
CA (1) CA2834049C (cg-RX-API-DMAC7.html)
ES (1) ES2625534T3 (cg-RX-API-DMAC7.html)
HU (1) HUE032820T2 (cg-RX-API-DMAC7.html)
IL (1) IL229023A (cg-RX-API-DMAC7.html)
PL (1) PL2701510T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012148994A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307961B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EP2911671B1 (en) * 2012-10-25 2018-06-27 Usher III Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
ES2693166T3 (es) * 2012-10-25 2018-12-07 Usher Iii Initiative, Inc. Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher
WO2016201266A1 (en) * 2015-06-11 2016-12-15 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy
US20220402895A1 (en) * 2019-10-23 2022-12-22 National University Of Singapore Method and System for Synthesising Compounds
WO2022011091A1 (en) 2020-07-09 2022-01-13 Usher Iii Initiative, Inc. Treatment of cancer, inflammatory diseases and autoimmune diseases
KR102785852B1 (ko) * 2021-12-03 2025-03-26 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009957A (es) 2001-04-30 2005-07-25 Vertex Pharma Inhibidores de la gsk-3 y estructuras cristalinas de la proteina gsk-3¦ y complejos de proteina.
GB0206723D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
WO2006050109A2 (en) * 2004-10-29 2006-05-11 Abbott Laboratories Novel kinase inhibitors
EP1816913A4 (en) 2004-11-01 2010-02-24 Univ Southern California NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND ILLNESS IN CONNECTION WITH THE ANGIOGENIC FUNCTION
CA2594621A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Pyrrolopyridines useful in the treatment of inflammation
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
US20070123508A1 (en) * 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
MX2008013204A (es) 2006-04-14 2008-10-22 Novartis Ag Uso de biarilcarboxamidas en el tratamiento de trastornos relacionados con la ruta hedgehog.
US7678792B2 (en) 2006-10-20 2010-03-16 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
WO2009039420A1 (en) * 2007-09-21 2009-03-26 Medivation Neurology, Inc. Methods and compositions for treating neuronal death mediated ocular diseases
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EP2723384B1 (en) 2011-06-22 2018-08-29 The General Hospital Corporation Treatment of proteinopathies
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
ES2693166T3 (es) 2012-10-25 2018-12-07 Usher Iii Initiative, Inc. Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher
EP2911671B1 (en) 2012-10-25 2018-06-27 Usher III Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2016201266A1 (en) 2015-06-11 2016-12-15 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy

Similar Documents

Publication Publication Date Title
JP2014515758A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2011511933A5 (cg-RX-API-DMAC7.html)
JP2011207901A5 (cg-RX-API-DMAC7.html)
JP2013537423A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2013520502A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2012514009A5 (cg-RX-API-DMAC7.html)
JP2009535358A5 (cg-RX-API-DMAC7.html)
JP2015512943A5 (cg-RX-API-DMAC7.html)
JP2013534248A5 (cg-RX-API-DMAC7.html)
JP2011509949A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2011518833A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
EA200870389A1 (ru) Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек
JP2015518831A5 (cg-RX-API-DMAC7.html)
JP2012025767A5 (cg-RX-API-DMAC7.html)
JP2016135784A5 (cg-RX-API-DMAC7.html)
JP2014511682A5 (cg-RX-API-DMAC7.html)
JP2011057686A5 (cg-RX-API-DMAC7.html)
JP2013532132A5 (cg-RX-API-DMAC7.html)
JP2012519182A5 (cg-RX-API-DMAC7.html)
JP2019059781A5 (cg-RX-API-DMAC7.html)